Compare Adaptive Biotechnologies Corp (ADPT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Novartis AG — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Novartis AG trades at $152.38 (market cap $295.37B). The key difference: Novartis AG is far larger — about 73.1× Adaptive Biotechnologies Corp's market cap, and Novartis AG pays a 3.07% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | NVS | |
|---|---|---|
Market Cap | $4.04B | $295.37B |
Sector | Health | Health |
52-Week High | $25.45 | $168.62 |
52-Week Low | $12.30 | $119.31 |
Enterprise Value | $4.10B | $336.69B |
Dividend Yield | — | 3.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
